Wednesday, January 13, 2016 12:43:21 PM
Takeda article: enGene Shines with a Host of Big Name Collaborations
http://marketexclusive.com/engene-shines-with-a-host-of-big-name-collaborations/1281/
http://marketexclusive.com/engene-shines-with-a-host-of-big-name-collaborations/1281/
Recent TAK News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/26/2026 10:12:38 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/26/2026 10:11:43 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/26/2026 10:11:12 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/26/2026 10:10:44 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/26/2026 10:10:10 AM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/22/2026 03:26:43 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/19/2026 10:10:41 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/13/2026 10:11:42 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/13/2026 10:03:04 AM
- Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results • Business Wire • 05/13/2026 06:38:00 AM
- 武田薬品、原発性免疫不全症(PID)を対象としたTAK-881の主要第2/3相臨床試験で良好なトップライン結果を発表 • Business Wire • 05/07/2026 01:25:00 PM
- Takeda annonce les premiers résultats positifs d’un essai clinique pivot de phase 2/3 sur le TAK-881 dans le traitement des déficits immunitaires primaires (DIP) • Business Wire • 05/06/2026 12:39:00 AM
- Takeda gibt positive Topline-Ergebnisse einer entscheidenden klinischen Phase-2/3-Studie mit TAK-881 bei primären Immundefekten (PID) bekannt • Business Wire • 05/06/2026 12:39:00 AM
- La Colombie-Britannique rembourse REVESTIVE(MD) (téduglutide pour injection) pour le traitement du syndrome de l'intestin court • PR Newswire (Canada) • 05/05/2026 12:00:00 PM
- British Columbia reimburses REVESTIVE® (teduglutide for injection) for the treatment of Short Bowel Syndrome • PR Newswire (Canada) • 05/05/2026 12:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/05/2026 10:31:45 AM
- Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID) • Business Wire • 05/04/2026 12:00:00 PM
- 1日1回投与の利便性を備えた経口薬であるザソシチニブによる、迅速かつ持続的な皮膚症状の改善効果および乾癬治療を変革する可能性を示唆した臨床試験結果の発表について • Business Wire • 03/28/2026 07:00:00 PM
- Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care • Business Wire • 03/28/2026 07:00:00 PM
- Alan Walshe Appointed General Manager of Takeda Canada • PR Newswire (Canada) • 03/02/2026 12:59:00 PM
- Alan Walshe est nommé directeur général de Takeda Canada • PR Newswire (Canada) • 03/02/2026 12:59:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/02/2026 11:04:16 AM
- Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis • Business Wire • 02/19/2026 05:00:00 PM
- U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 • Business Wire • 02/10/2026 08:15:00 AM
- Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE® Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead • Business Wire • 01/29/2026 06:37:00 AM
